Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

Biomarin Pharmaceutical Inc

Healthcare US BMRN

60.89USD
0.01(0.02%)

Last update at 2026-03-10T20:18:00Z

Day Range

60.6061.97
LowHigh

52 Week Range

61.1599.56
LowHigh

Fundamentals

  • Previous Close 60.88
  • Market Cap12732.85M
  • Volume1235152
  • P/E Ratio40.25
  • Dividend Yield-%
  • EBITDA426.09M
  • Revenue TTM2752.81M
  • Revenue Per Share TTM14.53
  • Gross Profit TTM 1612.37M
  • Diluted EPS TTM1.66

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 149.58M -75.35000M -42.32200M -94.81100M -142.70500M
Minority interest - - - - -
Net income 141.56M -64.08000M 859.10M -23.84800M -77.21100M
Selling general administrative 403.71M 354.30M 334.30M 680.92M 604.35M
Selling and marketing expenses 450.30M 405.10M 403.40M - -
Gross profit 1612.37M 1375.76M 1336.18M 1344.58M 1175.95M
Reconciled depreciation 101.97M 108.04M 105.17M 105.30M 95.67M
Ebit 57.55M -60.01300M -96.26000M -125.45700M -149.04100M
Ebitda 159.51M 48.03M -5.85000M -22.24300M -100.25000M
Depreciation and amortization 101.97M 108.04M 90.41M 103.21M 48.79M
Non operating income net other - 10.48M 16.60M 22.16M 22.28M
Operating income 57.55M -60.01300M -96.26000M -125.45700M -123.52400M
Other operating expenses 2054.48M 1928.62M 1956.71M 1829.51M 1664.74M
Interest expense 15.97M 15.34M 29.31M 23.46M 43.66M
Tax provision 8.02M -11.27000M -901.42200M -70.96300M -65.49400M
Interest income 18.03M 10.48M 16.61M 22.75M 22.83M
Net interest income 2.06M -4.85500M -12.69900M -0.71200M -20.83300M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 8.02M -11.27000M -901.42200M -70.96300M -65.49400M
Total revenue 2096.04M 1846.28M 1860.45M 1704.05M 1491.21M
Total operating expenses 1570.81M 1458.10M 1432.44M 1470.04M 1349.47M
Cost of revenue 483.67M 470.51M 524.27M 359.47M 315.26M
Total other income expense net 92.03M -15.33700M 53.94M 30.65M 51.65M
Discontinued operations - - - - -
Net income from continuing ops 141.56M -64.08000M 859.10M -23.84800M -77.21100M
Net income applicable to common shares 141.56M -64.08000M 859.10M -23.84800M -77.21100M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 6841.60M 6375.07M 6003.32M 5848.02M 4690.04M
Intangible assets 294.70M 338.57M 388.65M 417.27M 456.58M
Earning assets - - - - -
Other current assets 141.39M 104.52M 110.44M 129.93M 130.66M
Total liab 1890.05M 1771.92M 1732.59M 1742.02M 1567.66M
Total stockholder equity 4951.55M 4603.16M 4270.74M 4106.00M 3122.38M
Deferred long term liab - - - - -
Other current liab 354.24M 346.56M 329.40M 289.21M -13.03700M
Common stock 0.19M 0.19M 0.18M 0.18M 0.18M
Capital stock 0.19M 0.19M 0.18M 0.18M 0.18M
Retained earnings -621.55400M -789.19900M -925.68900M -861.60900M -1720.70900M
Other liab - 73.50M 113.69M 174.32M 98.12M
Good will 196.20M 196.20M 196.20M 196.20M 197.04M
Other assets - 1604.19M 1600.84M 1574.39M 612.00M
Cash 755.13M 724.53M 587.28M 649.16M 437.45M
Cash and equivalents - - - - -
Total current liabilities 1177.02M 588.88M 539.82M 492.55M 932.50M
Current deferred revenue 4.62M 0.71M 6.96M 0.15M 13.04M
Net debt 378.75M 358.49M 491.80M 425.99M 410.67M
Short term debt 502.66M 10.38M 10.46M 11.75M 361.88M
Short long term debt 493.88M - - - 361.88M
Short long term debt total 1133.88M 1083.02M 1079.08M 1075.14M 848.12M
Other stockholder equity 5611.56M 5396.04M 5181.81M 4983.57M 4822.75M
Property plant equipment - 1114.32M 1035.46M 1032.47M 1010.87M
Total current assets 2956.09M 2751.46M 2274.39M 2342.22M 1942.14M
Long term investments 611.13M 333.83M 507.79M 285.47M 411.98M
Net tangible assets - 4068.39M 3685.89M 3492.53M 2468.76M
Short term investments 318.68M 567.01M 426.60M 416.23M 316.36M
Net receivables 633.70M 461.32M 373.40M 448.35M 377.40M
Long term debt 593.10M 1083.02M 1079.08M 1075.14M 486.24M
Inventory 1107.18M 894.08M 776.67M 698.55M 680.27M
Accounts payable 315.51M 231.24M 193.00M 191.43M 570.62M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -38.64800M -3.86700M 14.43M -16.13900M 20.16M
Additional paid in capital - - - - -
Common stock total equity - - 0.18M 0.18M 0.18M
Preferred stock total equity - - - - -
Retained earnings total equity - - -925.68900M -861.60900M -1720.70900M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 121.22M 176.24M 151.76M 142.24M 122.01M
Deferred long term asset charges - - - - -
Non current assets total 3885.51M 3623.62M 3728.94M 3505.80M 2747.90M
Capital lease obligations 8.78M 10.38M 10.46M 11.75M 10.70M
Long term debt total - - 1079.08M 1075.14M 486.24M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -20.02900M -366.31300M 26.17M 108.19M 358.98M
Change to liabilities 59.02M 12.35M -93.89600M 80.22M 47.30M
Total cashflows from investing activities -20.02900M -366.31300M -53.62100M -31.02600M 264.35M
Net borrowings -2.60500M -3.03900M 210.76M -5.08700M -374.95300M
Total cash from financing activities -18.65000M -0.04800M 181.12M -74.67400M -388.00700M
Change to operating activities -5.10400M 19.83M -17.20600M -32.77500M -9.78800M
Net income 141.56M -64.08000M 859.10M -23.84800M -77.21100M
Change in cash 137.25M -61.88200M 211.71M -56.53600M -104.04600M
Begin period cash flow 587.28M 649.16M 437.45M 493.98M 598.03M
End period cash flow 724.53M 587.28M 649.16M 437.45M 493.98M
Total cash from operating activities 175.90M 304.54M 85.36M 48.26M 20.21M
Issuance of capital stock - - - - 0.00000M
Depreciation 101.97M 108.04M 105.17M 105.30M 95.67M
Other cashflows from investing activities 103.33M -24.64100M 34.52M 5.81M 49.99M
Dividends paid - - - - -
Change to inventory -68.26400M -35.06000M -61.15100M -107.55400M -23.74700M
Change to account receivables -82.03300M 65.57M -59.03500M -37.85200M -54.27400M
Sale purchase of stock 0.00000M 49.19M -50.00000M 31.61M 67.49M
Other cashflows from financing activities -16.04500M 2.99M 613.03M -69.58700M -13.05400M
Change to netincome 28.75M 185.24M -671.56800M 56.66M 19.62M
Capital expenditures 131.54M 119.22M 137.52M 163.41M 144.62M
Change receivables - 65.57M -59.03500M -37.85200M -54.27400M
Cash flows other operating - 23.17M -10.33500M -36.61700M -18.70200M
Exchange rate changes - -0.05700M -1.15000M 0.90M -0.59800M
Cash and cash equivalents changes - -61.88200M 211.71M -56.53600M -104.04600M
Change in working capital -96.38300M 66.03M -224.41700M -101.09200M -49.42000M
Stock based compensation 196.31M 197.26M 189.71M 159.87M 148.82M
Other non cash items -115.46600M 12.89M 44.71M -9.20300M -29.27300M
Free cash flow 44.36M 185.31M -52.15400M -115.14400M -124.41200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BMRN
Biomarin Pharmaceutical Inc		 0.01 0.02% 60.89 40.25 17.30 4.63 2.35 4.50 24.45
NVO
Novo Nordisk A/S		 -1.06 2.66% 38.72 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 38.88 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 38.30 8.31% 499.17 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -9.57 1.22% 772.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Biomarin Pharmaceutical Inc

770 Lindaro Street, San Rafael, CA, United States, 94901

Key Executives

Name Title Year Born
Mr. Jean-Jacques Bienaime M.B.A., MBA Chairman & CEO 1953
Mr. Brian R. Mueller Exec. VP of Fin. & CFO 1974
Dr. C. Greg Guyer Ph.D. CTO and Exec. VP of Global Manufacturing & Technical Operations 1962
Mr. Jeffrey Robert Ajer Exec. VP & Chief Commercial Officer 1962
Dr. Henry J. Fuchs M.D., Ph.D. Pres of Worldwide R&D 1958
Ms. Erin Burkhart Group VP & Chief Accounting Officer NA
Traci McCarty VP of Investor Relations NA
Mr. George Eric Davis Exec. VP, Gen. Counsel & Sec. 1971
Mr. Philip Lo Scalzo Sr. VP & Chief Compliance Officer NA
Ms. Humaira Serajuddin Sr. VP & Chief Marketing Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.